Information on COVID-19 rapidly emerged and expanded at the onset of the pandemic. As of May 2020 it included 17,998 publications. Over 1,500 of those publications addressed rheumatic disease-related topics. The purpose of this review is to identify specific threats to the validity of the COVID-19 literature and to recommend resources for practicing rheumatologists and their patients.
Researchers explore whether an online video intervention discussing appropriate treatment escalation improves willingness to change treatment in people living with rheumatoid arthritis (RA).
Researchers surveyed women over 40 who have had at least one pregnancy after their inflammatory arthritis diagnosis. They found that there is a need for better family planning care for women with childbearing potential.
This study analyzed PROMIS Fatigue SF scores in RA patients across the range of disease activity in order to evaluate score validity.
In Arthritis Care & Research, Yun et al. report using the National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) instruments in substitution for lengthier Patient-Reported Outcomes instruments such as the Routine Assessment of Patient Index Data 3 (RAPID3). 6,154 eligible patients contributed 11,275 observations using 4 PROMIS computer-adaptive testing instruments and the RAPID3. There was excellent agreement between the observed RAPID3 and predicted RAPID3 scores estimated using several PROMIS instruments. PROMIS may be used in place of RAPID3 and other patient global assessment components.
This article published in Rheumatology and Therapy by Radawski et al. identifies and quantifies the unmet needs perceived by United States patients with Rheumatoid Arthritis (RA) currently taking a disease-modifying antirheumatic drug (DMARD). 258 patients were surveyed and only 26% of patients reported that they were satisfied with their RA treatment. Patients not satisfied with their treatment reported higher rheumatic disease impact and half reported a current flare. There is a need for improved disease management among RA patients.
This is a proposal for a study to see if wearable digital technology that enables the regular passive collection of patients’ biometric and activity data is strongly related to data captured by patient-reported outcome measures. Participants in this study will be observed for a period of 6 months and will be registrants of ArthritisPower. The results of this study are expected to be published by the end of 2021.
In Clinical Rheumatology, Leverenz et al. report a study in which they investigated contraceptive methods used in young women with Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) and correlated the efficacy of the contraceptive methods with the use of concomitant rheumatic medications. Of the 164 women included, women with RA and PsA reported similar utilization of highly effective contraception methods and effective methods, but different utilization of ineffective methods and no methods. These proportions remained similar across subgroups taking methotrexate, anti-TNF biologics, and novel medications. Women with PsA were more likely to report no methods of contraception.
Hsiao et al. conducted a pretest/post test study with RA patients who had outpatient visits using 5 phenotypic groups that clarified patient desires. Clinicians were introduced to the phenotypic groups. The authors found greater evidence of shared decision-making in the post test phase of the study as patients were offered more choices and more visits in which patients vocalized their values and/or preferences and providers were more likely to base their recommendations on patients’ values and/or preferences. Allowing patients to consider a set of preference phenotypes can support shared decision-making.
In Arthritis Research & Therapy, Gavigan et al. report on Rheumatoid Arthritis (RA) patients’ beliefs on factors that influence their physician’s treatment decisions, reasons patients tolerate sub-optimal disease control, and perceived barriers to treatment optimization. Eligible participants were enrolled in the ArthritisPower registry and completed a survey on barriers to treatment optimization and patient-reported outcomes on symptoms of fatigue, sleep disturbance, and physical function. Most participants trusted their doctor’s treatment decisions and prioritized their physician’s treatment goals over their own.